|
1
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Buchler T, Klapka R, Melichar B, Brabec P,
Dusek L, Vyzula R and Abrahamova J: Sunitinib followed by sorafenib
or vice versa for metastatic renal cell carcinoma - data from the
Czech registry. Ann Oncol. 23:395–401. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rini BI, Escudier B, Tomczak P, Kaprin A,
Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME,
Rusakov IG, et al: Comparative effectiveness of axitinib versus
sorafenib in advanced renal cell carcinoma (AXIS): A randomised
phase 3 trial. Lancet. 378:1931–1939. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bennouna J, Sastre J, Arnold D, Österlund
P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C,
et al: ML18147 Study Investigators: Continuation of bevacizumab
after first progression in metastatic colorectal cancer (ML18147):
A randomised phase 3 trial. Lancet Oncol. 14:29–37. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rini BI, Melichar B, Ueda T, Grünwald V,
Fishman MN, Arranz JA, Bair AH, Pithavala YK, Andrews GI, Pavlov D,
et al: Axitinib with or without dose titration for first-line
metastatic renal-cell carcinoma: A randomised double-blind phase 2
trial. Lancet Oncol. 14:1233–1242. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Grothey A, Van Cutsem E, Sobrero A, Siena
S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et
al: CORRECT Study Group: Regorafenib monotherapy for previously
treated metastatic colorectal cancer (CORRECT): An international,
multicentre, randomised, placebo-controlled, phase 3 trial. Lancet.
381:303–312. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Melichar B, Bracarda S, Matveev V,
Alekseev B, Ivanov S, Zyryanov A, Janciauskiene R, Fernebro E,
Mulders P, Osborne S, et al: BEVLiN Investigators: A multinational
phase II trial of bevacizumab with low-dose interferon-α2a as
first-line treatment of metastatic renal cell carcinoma: BEVLiN.
Ann Oncol. 24:2396–2402. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fuchs CS, Tomasek J, Yong CJ, Dumitru F,
Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry
DR, et al: REGARD Trial Investigators: Ramucirumab monotherapy for
previously treated advanced gastric or gastro-oesophageal junction
adenocarcinoma (REGARD): An international, randomised, multicentre,
placebo-controlled, phase 3 trial. Lancet. 383:31–39. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Van Cutsem E, Tabernero J, Lakomy R,
Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko
V, Ferry D, et al: Addition of aflibercept to fluorouracil,
leucovorin, and irinotecan improves survival in a phase III
randomized trial in patients with metastatic colorectal cancer
previously treated with an oxaliplatin-based regimen. J Clin Oncol.
30:3499–3506. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Melichar B and Nemcová I: Eye
complications of cetuximab therapy. Eur J Cancer Care (Engl).
16:439–443. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Melichar B, Králíčková P, Hyšpler R,
Kalábová H, Cerman J Jr, Holečková P, Studentová H and Malířová E:
Hypomagnesaemia in patients with metastatic colorectal carcinoma
treated with cetuximab. Hepatogastroenterology. 59:366–371.
2012.PubMed/NCBI
|
|
13
|
Melichar B, Hyšpler R, Tichá A, Kalábová
H, Vitásková D, Zezulová M, Dvořák J, Cerman J Jr and Doležel M:
Intestinal permeability in patients with metastatic colon cancer
treated with patupilone. Clin Chem Lab Med. 52:1649–1655.
2014.PubMed/NCBI
|
|
14
|
Melichar B, Dvorák J, Hyspler R and Zadák
Z: Intestinal permeability in the assessment of intestinal toxicity
of cytotoxic agents. Chemotherapy. 51:336–338. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Melichar B, Kohout P, Brátová M, Solichová
D, Králícková P and Zadák Z: Intestinal permeability in patients
with chemotherapy-induced stomatitis. J Cancer Res Clin Oncol.
127:314–318. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Geiger S, Lange V, Suhl P, Heinemann V and
Stemmler HJ: Anticancer therapy induced cardiotoxicity, Review of
the literature. Anticancer Drugs. 21:578–590. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huddart RA, Norman A, Shahidi M, Horwich
A, Coward D, Nicholls J and Dearnaley DP: Cardiovascular disease as
a long-term complication of treatment for testicular cancer. J Clin
Oncol. 21:1513–1523. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Meinardi MT, Gietema JA, van der Graaf
WTA, van Veldhuisen DJ, Runne MA, Sluiter WJ, de Vries EG, Willemse
PB, Mulder NH, van den Berg MP, et al: Cardiovascular morbidity in
long-term survivors of metastatic testicular cancer. J Clin Oncol.
18:1725–1732. 2000.PubMed/NCBI
|
|
19
|
Zagars GK, Ballo MT, Lee AK and Strom SS:
Mortality after cure of testicular seminoma. J Clin Oncol.
22:640–647. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kalábová H, Melichar B, Ungermann L,
Doležal J, Krčmová L, Kašparová M, Plíšek J, Hyšpler R, Pecka M and
Solichová D: Intima-media thickness, myocardial perfusion and
laboratory risk factors of atherosclerosis in patients with breast
cancer treated with anthracycline-based chemotherapy. Med Oncol.
28:1281–1287. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Melichar B, Kalábová H, Krcmová L,
Kasparová M, Malírová E, Melicharová K, Pecka M, Hyspler R and
Solichová D: Serum homocysteine, cholesterol, retinol,
alpha-tocopherol, glycosylated hemoglobin and inflammatory response
during therapy with bevacizumab, oxaliplatin, 5-fluorouracil and
leucovorin. Anticancer Res. 29:4813–4820. 2009.PubMed/NCBI
|
|
22
|
Šrámek V, Melichar B, Indrakova J,
Študentová H, Kalábová H, Vrána D, Lukešová L, Adam T, Hlídková E,
Juráňová J, et al: Risk factors of atherosclerosis in patients with
history of breast cancer. Pteridines. 24:201–210. 2013. View Article : Google Scholar
|
|
23
|
Melichar B: Laboratory medicine and
medical oncology: T he tale of two Cinderellas. Clin Chem Lab Med.
51:99–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Floyd JD, Nguyen DT, Lobins RL, Bashir Q,
Doll DC and Perry MC: Cardiotoxicity of cancer therapy. J Clin
Oncol. 23:7685–7696. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Melichar B, Gregor J, Solichová D, Lukes
J, Tichý M and Pidrman V: Increased urinary neopterin in acute
myocardial infarction. Clin Chem. 40:338–339. 1994.PubMed/NCBI
|
|
26
|
Solichova D, Melichar B, Blaha V, Klejna
M, Vavrova J, Palicka V and Zadak Z: Biochemical profile and
survival in nonagenarians. Clin Biochem. 34:563–569. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Melichar B, Solichová D, Melicharová K,
Malírová E, Cermanová M and Zadák Z: Urinary neopterin in patients
with advanced colorectal carcinoma. Int J Biol Markers. 21:190–198.
2006.PubMed/NCBI
|
|
28
|
Ewer MS, Vooletich MT, Durand JB, Woods
ML, Davis JR, Valero V and Lenihan DJ: Reversibility of
trastuzumab-related cardiotoxicity, New insights based on clinical
course and response to medical treatment. J Clin Oncol.
23:7820–7826. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schmidinger M, Zielinski CC, Vogl UM,
Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M and Schmidinger H:
Cardiac toxicity of sunitinib and sorafenib in patients with
metastatic renal cell carcinoma. J Clin Oncol. 26:5204–5212. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dorff TB, Goldkorn A and Quinn DI:
Targeted therapy in renal cancer. Ther Adv Med Oncol. 1:183–205.
2009. View Article : Google Scholar : PubMed/NCBI
|
